Document Detail


Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management.
MedLine Citation:
PMID:  22563085     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Red blood cell transfusions have reduced morbidity and mortality for patients with sickle cell disease. Transfusions can lead to erythrocyte alloimmunization, however, with serious complications for the patient including life-threatening delayed hemolytic transfusion reactions and difficulty in finding compatible units, which can cause transfusion delays. In this review, we discuss the risk factors associated with alloimmunization with emphasis on possible mechanisms that can trigger delayed hemolytic transfusion reactions in sickle cell disease, and we describe the challenges in transfusion management of these patients, including opportunities and emerging approaches for minimizing this life-threatening complication.
Authors:
Karina Yazdanbakhsh; Russell E Ware; France Noizat-Pirenne
Related Documents :
22737075 - Highly efficient prion transmission by blood transfusion.
9500245 - Clinical evaluation of the new pall leucocyte-depleting blood cardioplegia filter (bc1).
1520635 - The screening for common drugs of abuse in whole blood by means of emit-ets and fpia-ad...
12932095 - Storage duration and polymerase chain reaction detection of plasmodium falciparum from ...
26185 - Skeletal muscle po2: indicator of peripheral tissue perfusion in haemorrhagic shock.
21714135 - Changes of circulatory-metabolic indices and skull biomechanics with brain activity dur...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review     Date:  2012-05-04
Journal Detail:
Title:  Blood     Volume:  120     ISSN:  1528-0020     ISO Abbreviation:  Blood     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-07-23     Completed Date:  2012-10-02     Revised Date:  2013-07-23    
Medline Journal Info:
Nlm Unique ID:  7603509     Medline TA:  Blood     Country:  United States    
Other Details:
Languages:  eng     Pagination:  528-37     Citation Subset:  AIM; IM    
Affiliation:
Laboratory of Complement Biology, New York Blood Center, 310 East 67th St, NewYork, NY 10065, USA. kyazdanbakhsh@nybloodcenter.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anemia, Sickle Cell / epidemiology,  immunology*,  physiopathology
Blood Group Incompatibility / immunology*
Blood Transfusion*
Erythrocytes / immunology*
Humans
Isoantigens / immunology*
Risk Factors
Grant Support
ID/Acronym/Agency:
R21 HL097350/HL/NHLBI NIH HHS; R21HL097350/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Isoantigens
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in...
Next Document:  Plasminogen is a key pro-inflammatory regulator that accelerates the healing of acute and diabetic w...